As investors brace for Wednesday’s congressional testimony from Federal Reserve Chairman Ben Bernanke, the stock market is up modestly. The Dow Jones Industrial Average is up 0.38%, the Nasdaq is up 0.86% and the S&P 500 is up 0.47%. Today’s market winners were both pharmaceutical companies who received a patent and FDA approval, respectively, for their drugs. Meanwhile, one of today’s losers is a biopharmaceutical company going through a market correction after a big rise Tuesday. Another loser is a digital tech firm who issued a profit warning.
Here are Monday’s market winners and losers.
Biggest Winners
Shares of Galena Biopharma (NASDAQ: GALE) are up 20% to $2.05 on trading volume of 12.1 million shares. The company received a patent for NeuVax, which is intended to help curb breat cancer recurrence. The 52-week high is $3.54.
Shares of Vivus (NASDAQ: VVUS) are up 13.37% to $30.00 on trading volume of 19.5 million shares. The FDA on Tuesday approved Qsymia, which is intended to help adults struggling with conditions related to obesity. Before Wednesday, the 52-week high was $29.99
Biggest Losers
Shares of Rovi (NASDAQ: ROVI) fell 40.37% to $10.52 on trading volume of 15.4 million shares. The digital media firm announced Wednesday that excluding special items, shareholders would likely earn 38 cents a share in 2012, compared to Bloomberg compiled analyst estimates of 57 cents . Before Wednesday, the 52-week low was $17.20.
Shares of StemCells Inc. (NASDAQ: STEM) fell 17.78% to $1.48 on trading volume of 5.6 million shares. Shares rose nearly 40% on Tuesday after the company announced solid results of a stem-cell therapy study targeted toward patients with Alzheimer’s. The stock is therefore correcting itself. The 52-week low is $0.59.
Samuel Weigley
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
